etoricoxib
Trade name: Gencox
Small moleculeexperimental
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data. — Wikipedia
Clinical trial activity
109 trials · 98 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
51
Phase 3
36
Phase 4
36
Earliest trial started Jun 1, 1998 (NCT00242489)
Timeline
Indications
Approved for
Studied for
- Abdominal Pain · Phase 3
- Achilles Tendon · Phase 4
- Acute Pain · Phase 4
- Anterior Cruciate Ligament Injuries · Phase 4
- Arthritis, Gouty · Phase 3
- Arthritis, Rheumatoid · Phase 4
- Arthroplasty · Phase 3
- Arthroscopy · Phase 4
- Axial Spondyloarthritis · Phase 4
- Back Pain · Phase 4
- Blood Loss, Surgical · Phase 3
- Bone Neoplasms · Phase 2
- Brachial Plexus Block · Phase 3
- Causalgia · Phase 2
- Contusions · Phase 4
- Drugs, Investigational · Phase 3
- Dysmenorrhea · Phase 3
- Etoricoxib · Phase 4
- Fasting · Phase 4
- Fibromyalgia · Phase 4
- Fluorouracil · Phase 4
- General Surgery · Phase 3
- Gout · Phase 4
- Hallux Valgus · Phase 4
- Headache · Phase 4
- Healthy Volunteers · Phase 1
- HIV · Phase 2
- Hysterectomy · Phase 3
- Laparoscopy · Phase 4
- Low Back Pain · Phase 4
- Myalgia · Phase 1
- Neuralgia · Phase 4
- Neuralgia, Postherpetic · Phase 4
- Ossification, Heterotopic · Phase 4
- Osteoarthritis · Phase 4
- Osteoarthritis, Hip · Phase 3
- Osteoarthritis, Knee · Phase 3
- Osteoarthropathy, Primary Hypertrophic · Phase 3
- Ovarian Diseases · Phase 4
- Ovariectomy · Phase 3
- Oxygen · Phase 4
- Pain · Phase 4
- Periodontitis · Phase 4
- Peripheral Nerve Injuries · Phase 2
- Pharmacokinetics · Early Phase 1
- Polyneuropathies · Phase 2
- Postoperative Pain · Phase 4
- Prostatic Neoplasms · Phase 2
- Radiculopathy · Phase 2
- Saliva · Phase 4
- Salpingectomy · Phase 3
- Shoulder Injuries · Phase 3
- Spondylitis, Ankylosing · Phase 3
- Sprains and Strains · Phase 4
- Superoxide Dismutase · Phase 4
- Surgical Wound · Phase 4
- Therapeutic Equivalency · Phase 1
- Thoracic Surgery · Phase 3
- Tonsillectomy · Phase 3
- Tooth · Phase 3
- Tooth Extraction · Phase 4
- Tuberculosis · Phase 1
- Vitiligo · Phase 4
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Selectively inhibits COX-2 (IC(50) = 1.1 +/- 0.1microM) compared with COX-1 IC(50)=116 +/- 8 microM.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1- Mol. weight
- 358.85 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaEtoricoxib ↗
- ChEMBLCHEMBL416146 ↗
Also known as
- 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
- 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
- 5-chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
- 5-chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
- 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine
- 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine
- arcoxia
- arcoxia
- arcoxia
- arcoxia
- arcoxia
- etobrix
- etocox
- etoricoxib
- etoricoxib
- etoricoxib
- etoricoxib
- etoricoxib
- etoricoxib
- etoricoxib
- etoricoxib
- etoricoxibum
- etoricoxibum
- etoxib
- etropain
- l791456
- l791456
- l-791456
- mk0663
- mk0663
- mk 0663
- mk-0663
- mk-0663
- mk-0663
- mk-0663
- mk-0663
- nucoxia
- torcoxia
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07143318 | Phase 1 | Jun 5, 2025 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT06863701 | Phase 3 | Jan 27, 2025 | Consultorio Médico "Dr. Rodrigo Suárez Otero", Laboratorios Silanes S.A. de C.V. |
| NCT06863662 | Phase 3 | Sep 18, 2024 | Laboratorios Silanes S.A. de C.V., OAXACA SITE MANAGEMENT ORGANIZATION, SC |
| NCT06791434 | Phase 4 | Aug 30, 2024 | MIT World Peace University |
| NCT05683574 | Phase 3 | Jun 30, 2024 | Eurofarma Laboratorios S.A. |
| NCT06517823 | Phase 3 | Apr 26, 2024 | Clinical Research Institute S.C., Laboratorios Silanes S.A. de C.V. |
| NCT06001112 | N/A | Sep 1, 2023 | Guangdong Provincial Hospital of Traditional Chinese Medicine |
| NCT05936281 | Phase 2 | Jun 30, 2023 | Fudan University, GeneScience Pharmaceuticals Co., Ltd. |
| NCT05536856 | Phase 4 | Oct 15, 2022 | Al Azhar University |
| NCT05142098 | Early Phase 1 (Phase 1) | Jan 1, 2022 | Dow University of Health Sciences, Duke University |
| NCT05256342 | N/A | Dec 30, 2021 | Technion University |
| NCT04968158 | Phase 3 | Nov 29, 2021 | Clinical Research Institute S.C., Icaro Investigación en Medicina S.A. de C.V., Laboratorios Silanes S.A. de C.V., Mediadvance Clinical S.A.P.I. de C.V. |
| NCT05791721 | Phase 4 | Oct 11, 2021 | University of Belgrade |
| NCT05995912 | Phase 2 | Sep 29, 2021 | Laboratorios Liomont, OAXACA SITE MANAGEMENT ORGANIZATION, SC |
| NCT04830579 | Phase 1 | Apr 10, 2021 | CRO ClinPharmInvest, Pharmtechnology LLC |
| NCT05014490 | Phase 1 | Feb 24, 2021 | Darnitsa Pharmaceutical Company, SFBC Anapharm |
| NCT05532280 | Phase 1 | Dec 28, 2020 | Future University in Egypt |
| NCT05533073 | Phase 1 | Aug 3, 2020 | Laboratorios Silanes S.A. de C.V., Universidad Autonoma de Nuevo Leon |
| NCT04462666 | Phase 2 | Jul 1, 2020 | Shanghai University of Traditional Chinese Medicine |
| NCT04883034 | N/A | Jun 1, 2020 | Gadjah Mada University |
Showing 20 of 109 trials
Page 1 / 6
Organizations
Research & Development (98)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 47 | 31 | 4 | 1998 |
| Laboratorios Silanes S.A. de C.V. | For profit | 5 | 5 | 2 | 2020 |
| University of Oslo | Academic/Hospital | 4 | 4 | 4 | 2004 |
| Karolinska Institute | Academic/Hospital | 3 | 3 | 2 | 2008 |
| Osaka University | Academic/Hospital | 3 | 1 | 3 | 2010 |
| Tel Aviv University | Academic/Hospital | 3 | 3 | 2 | 2006 |
| Chung Shan Medical University | Academic/Hospital | 2 | 2 | 2 | 2007 |
| Clinical Research Institute S.C. | For profit | 2 | 0 | 1 | 2021 |
| Foisor Orthopedics Clinical Hospital | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Hebrew University | Academic/Hospital | 2 | 1 | 1 | 2008 |
| OAXACA SITE MANAGEMENT ORGANIZATION, SC | For profit | 2 | 0 | 2 | 2021 |
| Technion University | Academic/Hospital | 2 | 1 | 2 | 2010 |
| University of Regensburg | Academic/Hospital | 2 | 2 | 1 | 2008 |
| Al Azhar University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Analgesic Solutions | For profit | 1 | 1 | 1 | 2011 |
| Argentine Tennis Association | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Autonomous University of Madrid | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Azienda Sanitaria Locale 4, Teramo | Government | 1 | 1 | 1 | 2011 |
| Baerum Hospital | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Bangladesh Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
98 organizations
Page 1 / 5